%0 Journal Article
%T Pimavanserin: A novel therapeutic option for Parkinson disease psychosis
%J Archive of "Neurology: Clinical Practice".
%D 2017
%R 10.1212/CPJ.0000000000000380
%X In the Review article ¡°Pimavanserin: A novel therapeutic option for Parkinson disease psychosis¡± by T. Hawkins and B.D. Berman,1 there are 2 minor errors. The last sentence in the third paragraph under ¡°Development of pimavanserin¡± should have read ¡°In addition, pimavanserin did not affect motor symptom severity and led to significant decreases in caregiver burden and improvements in nighttime sleep and daytime wakefulness.¡± The second-to-last sentence under ¡°Prescribing information¡± should read ¡°In the positive phase 3 trial of pimavanserin detailed above, there were 3 deaths; 2 in the treatment group and 1 in the placebo group.¡± The authors regret the errors
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5648209/